March 25 (Reuters)—CVS Health said on Wednesday its pharmacy benefit management (PBM) unit was laying out measures to prevent the stockpiling of malaria drug, hydroxychloroquine, which is being tested as a potential treatment for the coronavirus.
The company said it was also setting up limits on the use of azithromycin, a protease inhibitor and albuterol inhalers so that its PBM members with chronic conditions would be able to use the drugs, which have seen a surge in demand.
(Reporting by Manas Mishra in Bengaluru, Editing by Saumyadeb Chakrabarty)